Aclaris Therapeutics Eulerpool News

Aclaris Therapeutics Eulerpool News

Aclaris Therapeutics Notizie Azioni

Aclaris Therapeutics è seguito da molti giornalisti e investitori in tutto il mondo. Qui raccogliamo le più recenti notizie Aclaris Therapeutics.

• 18 settembre ·

  Yahoo
  Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
• 18 settembre ·

  TipRanks
  Aclaris Therapeutics’ ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment
• 17 settembre ·

  Yahoo
  Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
• 17 settembre ·

  TipRanks
  Aclaris Therapeutics (ACRS) Gets a Hold from H.C. Wainwright
• 17 settembre ·

  Thefly.com
  Aclaris announces first patient dosed in Phase 2a trial of ATI-2138
• 10 settembre ·

  Yahoo
  Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
• 19 agosto ·

  TipRanks
  H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)
• 10 agosto ·

  Yahoo
  Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
• 9 agosto ·

  Yahoo
  Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
• 9 agosto ·

  TipRanks
  Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review